Coronavirus News
-
Groundbreaking Possibility for Alertgy`s Non-Invasive Propriety Sensor for Detecting Covid-19
The ongoing COVID-19 pandemic necessitates the need for robust and reliable detection methods to tackle the spread of the virus and to alleviate the severe socio-economic consequences of the disease. Alertgy has partnered with Florida Atlantic University’s (FAU) Immunology and Virology Department to execute a collaborative study on the diagnostic capabilities of Alertgy’s newly ...
By Alertgy
-
(Viral) Vaccine Manufacturing
It is well accepted that vaccination is one of the most effective ways to prevent diseases. A vaccine helps the body’s immune system to recognize and fight pathogens like bacteria or viruses, which then keeps humans safe from the diseases they cause. Vaccines protect against a range of diseases, including measles, polio, diphtheria, tetanus, meningitis, influenza and cancer. ...
By Nuvonis
-
CEPI partners with Japan’s NEC Group to develop artificial intelligence-designed broadly protective betacoronavirus vaccine
April 8, 2022; OSLO, Norway/ TOKYO, Japan: CEPI, the Coalition for Epidemic Preparedness Innovations, and NEC Corporation (NEC: TSE: 6701) today announced the latest funding award under its US$200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other betacoronaviruses[1]. CEPI will provide seed funding of up to US$4.8m to NEC ...
-
Kephera Diagnostics receives $417,074 grant award from the Massachusetts Life Sciences Center to accelerate development of its rapid COVID-19 Antigen Test
Today, the Baker-Polito Administration announced that more than $1.5 million has been awarded to four projects that seek to increase testing capacity and provide solutions for coronavirus testing. The funding is through the Accelerating Coronavirus Testing Solutions (A.C.T.S.) Program, designed and administered by the Massachusetts Life Sciences Center, which supports projects focused on two core ...
-
Sensible Medical ReDS Lung Fluid Monitor to Help COVID-19 Patients in Italy, US and Other Countries
Hospitals treating COVID-19 patients are looking to use the radar-based technology, previously used in heart-failure patients, to monitor lungs of coronavirus patients. Sensible Medical has recently received urgent requests from hospitals around the world for its ReDS monitors systems to improve monitoring, treatment and resource use for COVID-19 patients. The company has already responded to ...
-
Viveve to Participate in Ladenburg Thalmann Healthcare Conference
ENGLEWOOD, CO / ACCESSWIRE / September 22, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, September 29, 2022, in New York City. Mr. Durbin will deliver the Viveve ...
-
Viveve to Participate in Alliance Global Partners Virtual MedTech Conference
ENGLEWOOD, CO / ACCESSWIRE / September 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Alliance Global Partners Virtual MedTech Conference, September 21, 2022. Mr. Durbin will provide an update on Viveve's ...
-
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
Emergex will manufacture the candidate universal influenza vaccine to cGMP standards for use in Phase I human trials Emergex’s universal influenza vaccine is a radically different approach to inducing influenza immunity by employing the use of a combination of: Highly conserved Class I peptides from non-structural proteins (NSP) representative of pandemic influenza A strains which ...
-
Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, ...
-
Role of oxygen generator in the epidemic period of coronavirus disease
Why is the oxygen generator important? Oxygen is a life-saving therapeutic gas, which is often used to treat patients with severe pneumonia and other respiratory diseases. Oxygen generator is an electric medical equipment. It first inhales air, removes nitrogen, then generates a continuous oxygen source, and delivers concentrated oxygen to patients who need respiratory support in a controlled ...
-
Positive FDA Guidance For Covid-19 Clinical Program
The Directors are pleased to advise that Biotron Limited (‘Biotron’ or ‘the Company’) has received guidance from the U.S. Food and Drug Administrations (‘FDA’) for development of its lead antiviral drug BIT225 as a potential treatment of Coronavirus Disease 2019 (COVID-19) infection in adults. The FDA’s guidance was received in written response to ...
-
Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer
IRVINE, CA, and HERSTAL, BELGIUM – May 19, 2022 – – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial stage precision diagnostics company, announces that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDX program, has finalized a foundational Local Coverage Determination (LCD) for Molecular Biomarkers to ...
By MDxHealth
-
Studies using SpyBiotech’s vaccine technology shows potential against Covid-19 and other Coronaviruses
A research paper demonstrating the potential of SpyBiotech’s SpyCatcher/SpyTag vaccine platform has been published in Science Advances. A Covid-19 vaccine being developed with SpyBiotech’s technology elicited a strong immune response in non-human primates, showing titres of neutralising antibodies (>104) that were above the range of protection provided by other licensed vaccines ...
-
Covid-19 or Seasonal Allergy: How to differentiate?
COVID-19 and seasonal allergies have many of the same signs and symptoms. However, there are some differences, knowing them can help you seek out the right treatments to provide effective relief. Unlike COVID-19, seasonal allergies aren't caused by a virus. Seasonal allergies are immune system responses triggered by exposure to allergens, such as seasonal tree or grass pollens. To complicate ...
-
Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
Both studies fully recruited, with data from the Dengue Fever study anticipated in the summer Preclinical data for Emergex’s Coronavirus vaccine candidate suggests that it could provide heterologous immunity to viruses from the same family Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major ...
-
Flottweg posts record figures for 2021
With a 14% increase in sales to 237.5 million euros and a 31% increase in incoming orders to 272.0 million euros, Flottweg SE draws a thoroughly positive balance for the 2021 financial year. The specialist in separation technology has therefore continued to record an upward trend. CFO Peter Frankfurter is very pleased with the final figures: "Although Flottweg has faced various difficulties, such ...
By Flottweg SE
-
Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a company addressing major global infectious disease threats through the development of fully synthetic CD8+ T-Cell Adaptive Vaccines, today announces that it has entered into an agreement with ATCC to progress preclinical development of its Yellow Fever booster vaccine program. ATCC is a non-profit ...
-
CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants
The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ ...
By Vaxxinit
-
Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron
Strong preclinical evidence of universal efficacy of zapnometinib against coronavirus variants of concernProf. Planz will continue to serve Atriva as Chairman of the Scientific Advisory Board The findings underscore the importance of new therapeutic approaches such as zapnometinib, which can maintain potent efficacy against all coronavirus strains, including Omicron Atriva Therapeutics ...
-
Neuropathix, Inc. Receives Patent Grant from India for its Novel Anti-Inflammatory Compounds
DOYLESTOWN, PA / ACCESSWIRE / January 18, 2022 / Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that the Company has been issued Indian Patent IN201617027528 specific to its global patent known as WO2015/106108A2 titled, “Novel Functionalized 1,3-Benzene Diols and their ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you